Medications and behavioural therapies remain the primary treatment options for substance use disorders. However, neuromodulation for addiction has emerged as a promising new approach. These non-invasive therapies use electrical, magnetic, or soundwave stimulation to alter neural circuits in the brain involved in reward and motivation.

The goal is to directly influence brain function. This helps reduce craving, improve self-control, and reset the brain’s reward pathways altered by repeated substance use.

Understanding the Brain Science

Substance use disorder is a chronic disease. It affects parts of the brain involved in reward seeking, judgement, decision-making, learning, memory, and behaviour. Repeated exposure to drugs or alcohol overstimulates critical neurocircuits. This leads to artificially high levels of neurotransmitters like dopamine.

Over time, this weakens the brain’s natural reward response. It also impairs the prefrontal cortex’s ability to regulate impulse control and decision-making. Brain stimulation therapy for addiction aims to stimulate key regions directly or indirectly. These include the prefrontal cortex and the nucleus accumbens—the brain’s reward hub.

Proven Techniques Now Applied to Addiction

Neuromodulation has been developed and tested to address neurological and psychiatric disorders. These include Parkinson’s disease, Alzheimer’s disease, obsessive-compulsive disorder, depression, and chronic pain. Research shows stimulating specific brain areas can restore more balanced activity. It strengthens communication between brain regions involved in behaviour, emotion, and self-control.

Researchers are now exploring these techniques as treatment for substance use disorders. Early studies show encouraging reductions in craving and relapse risk. However, the science is still in early stages.

Repetitive Transcranial Magnetic Stimulation (rTMS)

This non-invasive technique uses magnetic pulses delivered through an electromagnetic coil placed on the scalp. It activates specific brain regions, particularly the prefrontal cortex. Through repeated sessions, neuromodulation for addiction using rTMS can strengthen neural pathways in underactive regions. It also suppresses overactive reward circuits that drive cravings.

A 2024 literature review and meta-analysis included 51 rTMS-specific studies. These involved 2,406 participants. The findings showed rTMS had positive outcomes in reducing craving and substance use. This applied across tobacco, stimulants, and opioid use disorders.

For alcohol use disorder treatment, rTMS studies showed promising results. Multi-session protocols produced significantly greater reductions in both craving and drinking frequency. This was compared to single sessions. High-frequency stimulation and repeated sessions were especially effective. rTMS has also received FDA approval for tobacco cessation.

Transcranial Direct Current Stimulation (tDCS)

This technique applies low-intensity electrical current through electrodes on the scalp. It subtly alters brain activity. Instead of directly activating neurons, it adjusts their responsiveness. This makes them more or less likely to respond to craving or impulse control signals.

The same 2024 review included 36 tDCS studies with 1,582 participants. Brain stimulation therapy for addiction using tDCS showed similar efficacy to rTMS. This applied to treating tobacco, stimulant, and opioid use disorders. It helped reduce cravings and substance use. The treatment appeared most effective when delivered in longer sessions over multiple treatment days.

Deep Brain Stimulation (DBS)

Deep brain stimulation involves a surgical procedure. It places thin electrodes into specific regions of the brain to deliver continuous electrical pulses. These signals help correct abnormal neural activity in targeted areas.

A systematic review synthesised 26 studies involving 71 participants. They received DBS treatment for alcohol, opioid, stimulant, and tobacco use disorders. Nearly 27% of patients remained abstinent throughout follow-up periods. These ranged from 100 days to eight years. Nearly half showed significant reductions in substance use.

Most notably, 50% of participants who received DBS to treat opioid use disorder remained abstinent during follow-up. Nearly 67% of those treated for methamphetamine use disorder also remained abstinent. However, researchers emphasise that DBS remains experimental. This is due to cost, surgical risk, and limited availability. It’s best suited for severe cases.

Focused Ultrasound (FUS)

This cutting-edge approach uses low-intensity sound waves. They’re precisely targeted through the skull and guided by MRI. This adjusts deep brain structures without surgical implantation. The technique targets parts of the brain associated with reward and craving circuitry.

A 2025 pilot study tested FUS in eight participants with severe opioid use disorder. After a single 20-minute session, participants showed an average 91% reduction in opioid cravings. This was from baseline to 90 days post-treatment. Nearly 88% of participants were abstinent at 30 days. About 62.5% remained abstinent at three months.

Brain scans showed the technique was safe and well-tolerated. They also demonstrated normalised brain connectivity. Whilst at a very early stage, these findings suggest FUS is a feasible form of neuromodulation for addiction treatment.

Transcutaneous Auricular Neurostimulation (tAN)

This technique delivers mild electrical impulses through small electrodes placed on the outer ear. It targets key nerve pathways that help regulate stress, heart rate, and relaxation. By activating these pathways, tAN aims to calm the body’s stress response. This eases the discomfort of opioid withdrawal.

A 2022 study found tAN reduced opioid withdrawal symptoms by 42% within 30 minutes. Within one hour, the reduction reached 46%. Over days two to five, participants achieved up to a nearly 75% average reduction in withdrawal symptoms.

The Road Ahead

Current evidence suggests that brain stimulation therapy for addiction holds significant promise. Non-invasive techniques like rTMS and tDCS currently have the most research support. These approaches offer new hope for individuals struggling with substance use disorders. This is especially true for those who haven’t responded to conventional treatments.

However, researchers emphasise important limitations. Most studies have been short-term and involved small samples. They also lacked standardised protocols. Larger, randomised trials with longer follow-up periods are needed. These will confirm effectiveness and identify optimal treatment parameters. They’ll also determine which patients are most likely to benefit.

As the science advances, neuromodulation for addiction may become an important complement to existing treatment approaches. It offers a powerful tool to help reset the brain’s reward pathways and support lasting recovery.

Source: Addiction Policy